Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma

PLoS One. 2019 Feb 25;14(2):e0212813. doi: 10.1371/journal.pone.0212813. eCollection 2019.

Abstract

Follicular lymphoma (FL) is an indolent but largely incurable disease. Some patients suffer histological transformation to a more aggressive subtype with poorer prognosis. This study aimed to improve our understanding of the genetics underlying FL histological transformation, and to identify genetic drivers or promoters of the transformation by elucidating the differences between FL samples from patients who did and did not transform. We conducted targeted massive parallel sequencing of 22 pre-transformed FL/transformed diffuse large B-cell lymphoma pairs and 20 diagnostic samples from non-transformed FL patients. Additionally, 22 matched samples from 11 transformed FL patients (pre-transformed FL and diffuse large B-cell lymphoma) and 9 non-transformed FLs were studied for copy number variation using SNP arrays. We identified recurrently mutated genes that were enriched at transformation, most notably LRP1B, GNA13 and POU2AF1, which have roles in B-cell differentiation, GC architecture and migration. Mutations in POU2AF1 might be associated with lower levels of expression, were more frequent in transformed FLs, and seemed to be specific to transformed- compared with de novo-diffuse large B-cell lymphomas. Pre-transformed FLs carried more mutations per sample and had greater subclonal heterogeneity than non-transformed FLs. Finally, we identified four mutated genes in FL samples that differed between patients who did and did not transform: NOTCH2, DTX1, UBE2A and HIST1H1E. The presence of mutations in these genes was associated with shorter time to transformation when mutated in the FL biopsies. This information might be useful for identifying patients at higher risk of transformation.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aged
  • B-Lymphocytes* / metabolism
  • B-Lymphocytes* / pathology
  • Biopsy
  • Cell Differentiation / genetics
  • Cell Transformation, Neoplastic* / genetics
  • Cell Transformation, Neoplastic* / metabolism
  • Cell Transformation, Neoplastic* / pathology
  • Female
  • Follow-Up Studies
  • Humans
  • Lymphoma, Follicular* / genetics
  • Lymphoma, Follicular* / metabolism
  • Lymphoma, Follicular* / pathology
  • Lymphoma, Large B-Cell, Diffuse* / genetics
  • Lymphoma, Large B-Cell, Diffuse* / metabolism
  • Lymphoma, Large B-Cell, Diffuse* / pathology
  • Male
  • Middle Aged
  • Mutation*
  • Neoplasm Proteins* / genetics
  • Neoplasm Proteins* / metabolism

Substances

  • Neoplasm Proteins

Grants and funding

This work was supported by the Spanish Ministry of Economy and Competence (MINECO): SAF2013-47416-R; ISCIII-MINECO AES-FEDER (Plan Estatal de I+D+I 2008-2011 and 2013-2016) (RD12/0036/0060 (MAP), RD12/0036/0041(MP), PI14/00221(MSB), PIE14/0064(MP), PI16/01294(MAP), CIBERONC CB16/12/00291(MAP), DTS17/00039(MSB)), PT13/0010/0007 (MAP) and by Dirección General de Universidades e Investigación Consejería de Educación e Investigación de la Comunidad de Madrid (B2017/BMD-3778); JG-R is a recipient of an iPFIS predoctoral fellowship (IFI14/00003), PM is supported by a Juan Rodés contract (JR14/0018) and MSB currently holds a Miguel Servet II contract (CPII16/00024), supported by ISCIII-MINECO AES-FEDER (Plan Estatal I+D+I 2013-2016) and the Fundación de Investigación Biomédica Puerta de Hierro; DP-C by a SEOM-Rio Hortega 2015 contract and LP by Plan de Empleo Juvenil from Comunidad de Madrid (Madrid I+D+I); FB by a grant from the GELU Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.